
CLAIMS

1. Compounds of formula (I)



(I)

wherein

W1, W5, W6 denotes independently from one another N or CH;

W2 denotes N or CR6;

W3 denotes N or CR5;

under the proviso that at least one of W1, W2, W3, W5 or W6 denotes N;

X denotes NR1, Alk, O, S or C=R1;

R1 denotes H, A or Cyc;

R5 denotes H, A, Hal, OY, CN, -Alk-OY, COOY, -CO-NYY, SA, SO_2A, NYY, -OAlk-OY, -OAlk-NYY, -OAlk-NY-COOY, -OAlk-Het^3, NO_2, -NH-Alk-COOY, -NH-CO-Alk-OY, -NH-CO-Alk-OCOY, -NH-CO-Alk-NYY, -NH-CO-NYY, -NH-CO-Het^3, -NY-COOY, -NY-SO_2Y, -NH-SO_2-NYY, -NH-Het^2, -NH-R2, -NY-CO-R2, -NY-CO-NY-R2, -NY-COO-R2, -NY-SO_2-R2, -NY-SO_2-NY-R2, -OAr, -NY-Ar, -OHet^1, NY-Het^1, -CO-NYY-NYY, -CO-Het^3 or -CO-NH-Alk-Het^3;

R1, R5 together also denote -CH=CH-, -C(Y)=N-, -N=C(Y)-, -C(COY)=N-, -C(CO-R2)=N-, -CO-NH-, -NH-CO-, -SO_2-NH-, -NH-SO_2-, =CH-NH-CO-,

-CH-N(Alk-Het^3)-CO-, -CH=C(NO_2)- or -CH=C(Hal)-;

R6 denotes H, A, Hal, OY, CN, -Alk-OY, COOY, -CO-NYY, NYY, -NY-COOY, -NH-Alk-NYY, -NH-COA, -NH-CO-Alk-NYY, -NH-Het^2, Het^3, -OAr, -NY-Ar, -OHet^1, NY-Het^1, Het^1, -NH-SO_2Y, -NH-Cyc, -NH-Het^3, -NH-Alk-Het^3, -NH-Alk-OY, -NH-CO-NYY, -NH-CO-Het^3, -CO-NH-Het^3, -NH-CO-Alk-OY, -NH-CO-Alk-Het^3, -CO-NH-Alk-Het^3, -NH-CO-Alk-NH-COOY or -CO-NH-Alk-NYY;

R2 denotes a monocyclic carboaryl having 5-8 C atoms or a monocyclic heteroaryl having 2-7 C atoms and 1-4 N, O and/or S atoms, each of which can be substituted by at least one substituent selected from the group of A, Hal, CN, NYY, OY, =O;

R3, R4 denotes independently from one another H, A, Hal, CN, NYY, OY, -OAlk-NYY, -OAlk-OY;

Y denotes H or A;

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms can be replaced by Hal;

Cyc denotes cycloalkyl having 3-7 C atoms, in which 1-4 H atoms can be replaced independently from one another by A, Hal and/or OY;

Alk denotes alkylene having 1-6 C atoms, in which 1-4 H atoms can be replaced independently of one another by Hal and/or CN;

Ar denotes a saturated, unsaturated or aromatic, mono- or bicyclic carbocycle having 6-10 C atoms, which can be substituted by at least one substituent selected from the group of Het^3, A, Hal, OY, COOY, -Alk-OY, -Alk-SO_2, -Alk-Het^1, -OAlk-Het^1, NYY, -CO-NYY, -SO_2NYY, CN;

Het[1] denotes a monocyclic heteroaryl having 2-7 C atoms and 1-4 N, O and/or S atoms,
which can be substituted by at least one substituent selected from the group of A, Hal, OY, COOY, -Alk-OY, -Alk-SO_2, NYY, -CO-NYY, -SO_2NYY, CN;

Het[2] denotes a bicyclic heteroaryl having 2-9 C atoms and 1-4 N atoms, which can be substituted by at least one substituent selected from the group of R2, A, Hal, OY, COOY, -Alk-OY, -Alk-SO_2, NYY, -CO-NYY, -SO_2NYY, CN;

Het[3] denotes a saturated monocyclic heterocycle having 2-7 C atoms and 1-4 N, O and/or S atoms,
which can be substituted by at least one substituent selected from the group of A, Hal, OY, COOY, -Alk-OY, -Alk-SO_2, NYY, -CO-NYY, -SO_2NYY, CN;

and

Hal denotes F, Cl, Br or I;

and/or physiologically acceptable salts thereof.

2. Compounds according to claim 1, wherein

W1 denotes N or CH, preferably N,
W2 denotes CR6,
W3 denotes N or CR5, preferably CR5,
W5 denotes N or CH, preferably CH, and
W6 denotes CH.

3. Compounds according to claim 1 or 2, wherein

R5 denotes H, A, OA, CN, -Alk-OY, COOY, -CO-NYY, NYY, -OAlk-OY, -OAlk-NYY, -OAlk-Het[3], -NH-CO-Alk-NYY, Hal, -CO-NYY-NYY or -CO-NH-Alk-Het[3];
preferably H, OA, CN, -Alk-OH, COOA, -CO-NHA, NH_2, -OAlk-OY, -OAlk-NAA, -OAlk-Het[3], -NH-CO-Alk-NAA, Cl, -CO-NHA-NAA or -CO-NH-Alk-Het[3];

or

R1, R5 together also denote -CH=CH-, -CO-NH-, -SO_2-NH-, -N=C(Y)-, -CH=C(NO_2)- or -CH=C(Hal)-;
preferably –CH=CH-, -N=C(H)- or -CH=C(Br)-.


4. Compounds according to any of claims 1 to 3, wherein

R6 denotes H, A, OA, NH_2, -NH-COA, -CO-NHA, Hal, NAA, -NH-CO-Alk-NYY, -NH-Alk-Het^3, -NH-CO-NH_2, -NH-CO-Het^3, -CO-NH-Het^3, -NH-CO-Alk-OH or -NH-CO-Alk-NH-COOA.

5. Compounds according to any of claims 1 to 4, wherein

R2 denotes phenyl, pyridyl, pyrazolyl or pyrazinyl, each of which can be mono-, di- or trisubstituted by at least one substituent selected from the group of F, Cl, Br, CH_3, CF_3, CN, OCH_3, OCF_3.

6. Compounds according to claim 1, having sub-formula (II)



(II)

wherein

W1, W5 denotes independently from one another N or CH;

W3 denotes N or CR5;

under the proviso that at least one of W1, W3 or W5 denotes N;

R1, R3, R4 denotes independently from one another H or A;

R5 denotes H, A, OA, CN, -Alk-OY, COOY, -CO-NYY, NYY, -OAlk-OY, -OAlk-NYY, -OAlk-Het^3, -NH-CO-Alk-NYY, Hal, -CO-NYY-NYY or -CO-NH-Alk-Het^3;

R1, R5 together also denote -CH=CH-, -CO-NH-, -SO_2-NH-, -N=C(Y)-, -CH=C(NO_2)- or -CH=C(Hal)-;

R6 denotes H, A, OA, NH_2, -NH-COA, -CO-NHA, Hal, NAA, -NH-CO-Alk-NYY, -NH-Alk-Het^3, -NH-CO-NH_2, -NH-CO-Het^3, -CO-NH-Het^3, -NH-CO-Alk-OH or -NH-CO-Alk-NH-COOA;

R2 denotes phenyl, pyridyl, pyrazolyl or pyrazinyl, each of which can be mono-, di- or trisubstituted by at least one substituent selected from the group of F, Cl, Br, CH_3, CF_3, CN, OCH_3, OCF_3;

Y denotes H or A;

A denotes unbranched or branched alkyl having 1-4 C atoms, in which 1-5 H atoms can be replaced by F and/or Cl;

Alk denotes alkylene having 1-3 C atoms;

Het^3 denotes piperazine, piperidine, morpholine, pyrrolidine, piperidone, morpholinone or pyrrolidone, which can be monosubstituted by A, Hal, COOY or NYY;


and

Hal denotes F, Cl or Br;

and/or physiologically acceptable salts thereof.

7. Compounds according to any of claims 1 to 6, which are selected from the group of:


1




2




3




5




6




9




65




67




70




71





72





73





10 


11 


12 


13 


14 


15 


77 


78 


80 


81 


82 


85 


16 


17 


18 


20 


21 


22 


86 


87 


88 


89 


90 


91 


23 


25 


26 


28 


29 


30 


92 


94 


95 


98 


99 


100 


32 


33 


34 


37 


38 


40 


104 


105 


106 


107 


109 


110 


41 


42 


43 


44 


47 


48 


111 


112 


113 


114 


115 


117 


49 


50 


51 


52 


53 


54 


121 


125 


129 


130 


131 


133 


55 


57 


58 


60 


62 


63 


135 

139 

140 

141 


143 

144 

and/or physiologically acceptable salts thereof.

8. Process for manufacturing a compound of formula (I) comprising the steps of:


(a) reacting a compound of formula (IV)



(IV)

wherein R7 denotes Hal, OY or NYY; and
R2, R3, R4, Hal and Y have the meaning according to claim 1,


with a compound of formula (V)



(V)

wherein X, R1, W1, W2, W3, W5 and W6 have the meaning according to claim 1 under the proviso that R1, R5 together are excluded,

to yield a compound of formula (I)




(I)

wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim 1 under the proviso that R1, R5 together are excluded,

and optionally

(b) converting a base or an acid of the compound of formula (I) into a salt thereof.

9. Intermediate compounds of formula (IV)



(IV)

wherein

R2 denotes phenyl or pyridyl,
each of which can be substituted by at least one substituent selected from the group of A, Hal, CN, NYY, OY, =O,
under the proviso that (i) unsubstituted phenyl is excluded if R7 is OY and (ii) unsubstituted pyridyl is excluded if R7 is NYY;

R3, R4 denotes independently from one another H, A, Hal, CN, NYY, OY, -OAlk-NYY, -OAlk-OY;

R7 denotes Hal, OY or NYY;

Y denotes H or A;


A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms can be replaced by Hal;

Alk denotes alkylene having 1-6 C atoms, in which 1-4 H atoms can be replaced independently of one another by Hal and/or CN;

Hal denotes F, Cl, Br or I;

and/or physiologically acceptable salts thereof.


10. Compounds according to claim 9, which are selected from the group of:



and/or physiologically acceptable salts thereof.

11. Process for manufacturing an intermediate compound of formula (IV) comprising the steps of:


(a) reacting a compound selected from the group of boronic acid, boronic ester, tin organics and boron triflates, each of which is substituted by R2 having the meaning according to claim 9, with a compound of formula (XI-A)



(XI-A)

wherein R3, R4, R7 and Hal have the meaning according to claim 9,

to yield a compound of formula (IV)



(IV)

wherein R2, R3, R4 and R7 have the meaning according to claim 9,

and optionally

(b) converting a base or an acid of the compound of formula (IV) into a salt thereof.

12. Use of compounds according to any of claims 1 to 7 and/or physiologically acceptable salts thereof for inhibiting ATP consuming proteins, preferably TGF-beta receptor kinase, wherein an IC50 of the compounds amounts to less than 1 µM, preferably less than 0.1 µM.


13. Medicament comprising at least one compound according to any of claims 1 to 7 and/or physiologically acceptable salts.

14. Pharmaceutical composition comprising as active ingredient an effective amount of at least one compound according to any of claims 1 to 7 and/or physiologically acceptable salts thereof together with pharmaceutically tolerable adjuvants, optionally in combination with at least another active ingredient selected from the group of (1) estrogen receptor modulators, (2) androgen receptor modulators, (3) retinoid receptor modulators, (4) cytotoxic agents, (5) antiproliferative agents, (6) prenyl-protein transferase inhibitors, (7) HMG-CoA reductase inhibitors, (8) HIV protease inhibitors, (9) reverse transcriptase inhibitors and (10) further angiogenesis inhibitors.

15. Compounds according to any of claims 1 to 7 and/or physiologically acceptable salts thereof for use in the prophylactic or therapeutic treatment and/or monitoring of diseases selected from the group of cancer, tumor growth, metastatic growth, fibrosis, restenosis, HIV infection, neurodegenerative disorders, atherosclerosis, inflammation and disorders of wound healing, angiogenesis, cardiovascular system, bone, CNS and/or PNS.

CLAIMS

1. Compounds of formula (I)



(I)

wherein

W1, W5, W6 denotes independently from one another N or CH;

W2 denotes N or CR6;

W3 denotes N or CR5;

under the proviso that at least one of W1, W2, W3, W5 or W6 denotes N;

X denotes NR1, Alk, O or S;

R1 denotes H, A or Cyc;

R5 denotes H, A, Hal, OY, CN, -Alk-OY, COOY, -CO-NYY, SA, SO_2A, NYY, -OAlk-OY, -OAlk-NYY, -OAlk-NY-COOY, -OAlk-Het^3, NO_2, -NH-Alk-COOY, -NH-CO-Alk-OY, -NH-CO-Alk-OCOY, -NH-CO-Alk-NYY, -NH-CO-NYY, -NH-CO-Het^3, -NY-COOY, -NY-SO_2Y, -NH-SO_2-NYY, -NH-Het^2, -NH-R2, -NY-CO-R2, -NY-CO-NY-R2, -NY-COO-R2, -NY-SO_2-R2, -NY-SO_2-NY-R2, -OAr, -NY-Ar, -OHet^1, NY-Het^1, -CO-NYY-NYY, -CO-Het^3 or -CO-NH-Alk-Het^3;

R1, R5 together also denote -CH=CH-, -C(Y)=N-, -N=C(Y)-, -C(COY)=N-, -C(CO-R2)=N-, -CO-NH-, -NH-CO-, -SO_2-NH-, -NH-SO_2-, =CH-NH-CO-,

-CH-N(Alk-Het^3)-CO-, -CH=C(NO_2)- or -CH=C(Hal)-;

R6 denotes H, A, Hal, OY, CN, -Alk-OY, COOY, -CO-NYY, NYY, -NY-COOY, -NH-Alk-NYY, -NH-COA, -NH-CO-Alk-NYY, -NH-Het^2, Het^3, -OAr, -NY-Ar, -OHet^1, NY-Het^1, Het^1, -NH-SO_2Y, -NH-Cyc, -NH-Het^3, -NH-Alk-Het^3, -NH-Alk-OY, -NH-CO-NYY, -NH-CO-Het^3, -CO-NH-Het^3, -NH-CO-Alk-OY, -NH-CO-Alk-Het^3, -CO-NH-Alk-Het^3, -NH-CO-Alk-NH-COOY or -CO-NH-Alk-NYY;

R2 denotes a monocyclic carboaryl having 5-8 C atoms or a monocyclic heteroaryl having 2-7 C atoms and 1-4 N, O and/or S atoms, each of which can be substituted by at least one substituent selected from the group of A, Hal, CN, NYY, OY, =O;

R3, R4 denotes independently from one another H, A, Hal, CN, NYY, OY, -OAlk-NYY, -OAlk-OY;

Y denotes H or A;

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms can be replaced by Hal;

Cyc denotes cycloalkyl having 3-7 C atoms, in which 1-4 H atoms can be replaced independently from one another by A, Hal and/or OY;

Alk denotes alkylene having 1-6 C atoms, in which 1-4 H atoms can be replaced independently of one another by Hal and/or CN;

Ar denotes a saturated, unsaturated or aromatic, mono- or bicyclic carbocycle having 6-10 C atoms, which can be substituted by at least one substituent selected from the group of Het^3, A, Hal, OY, COOY, -Alk-OY, -Alk-SO_2, -Alk-Het^1, -OAlk-Het^1, NYY, -CO-NYY, -SO_2NYY, CN;

Het[1] denotes a monocyclic heteroaryl having 2-7 C atoms and 1-4 N, O and/or S atoms, which can be substituted by at least one substituent selected from the group of A, Hal, OY, COOY, -Alk-OY, -Alk-SO_2, NYY, -CO-NYY, -SO_2NYY, CN;

Het[2] denotes a bicyclic heteroaryl having 2-9 C atoms and 1-4 N atoms, which can be substituted by at least one substituent selected from the group of R2, A, Hal, OY, COOY, -Alk-OY, -Alk-SO_2, NYY, -CO-NYY, -SO_2NYY, CN;

Het[3] denotes a saturated monocyclic heterocycle having 2-7 C atoms and 1-4 N, O and/or S atoms, which can be substituted by at least one substituent selected from the group of A, Hal, OY, COOY, -Alk-OY, -Alk-SO_2, NYY, -CO-NYY, -SO_2NYY, CN;

and

Hal denotes F, Cl, Br or I;

and/or physiologically acceptable salts thereof.

2. Compounds according to claim 1, wherein

W1 denotes N or CH, preferably N,

W2 denotes CR6,

W3 denotes N or CR5, preferably CR5,

W5 denotes N or CH, preferably CH, and

W6 denotes CH.

3. Compounds according to claim 1 or 2, wherein

R5 denotes H, A, OA, CN, -Alk-OY, COOY, -CO-NYY, NYY, -OAlk-OY, -OAlk-NYY, -OAlk-Het[3], -NH-CO-Alk-NYY, Hal, -CO-NYY-NYY or -CO-NH-Alk-Het[3];
preferably H, OA, CN, -Alk-OH, COOA, -CO-NHA, NH_2, -OAlk-OY, -OAlk-NAA, -OAlk-Het[3], -NH-CO-Alk-NAA, Cl, -CO-NHA-NAA or -CO-NH-Alk-Het[3];

or

R1, R5 together also denote -CH=CH-, -CO-NH-, -SO_2-NH-, -N=C(Y)-, -CH=C(NO_2)- or -CH=C(Hal)-;
preferably –CH=CH-, -N=C(H)- or -CH=C(Br)-.


4. Compounds according to any of claims 1 to 3, wherein

R6 denotes H, A, OA, NH_2, -NH-COA, -CO-NHA, Hal, NAA, -NH-CO-Alk-NYY, -NH-Alk-Het^3, -NH-CO-NH_2, -NH-CO-Het^3, -CO-NH-Het^3, -NH-CO-Alk-OH or -NH-CO-Alk-NH-COOA.

5. Compounds according to any of claims 1 to 4, wherein

R2 denotes phenyl, pyridyl, pyrazolyl or pyrazinyl, each of which can be mono-, di- or trisubstituted by at least one substituent selected from the group of F, Cl, Br, CH_3, CF_3, CN, OCH_3, OCF_3.

6. Compounds according to claim 1, having sub-formula (II)



(II)

wherein

W1, W5 denotes independently from one another N or CH;

W3 denotes N or CR5;

under the proviso that at least one of W1, W3 or W5 denotes N;

R1, R3, R4 denotes independently from one another H or A;

R5 denotes H, A, OA, CN, -Alk-OY, COOY, -CO-NYY, NYY, -OAlk-OY, -OAlk-NYY, -OAlk-Het^3, -NH-CO-Alk-NYY, Hal, -CO-NYY-NYY or -CO-NH-Alk-Het^3;

R1, R5 together also denote -CH=CH-, -CO-NH-, -SO_2-NH-, -N=C(Y)-, -CH=C(NO_2)- or -CH=C(Hal)-;

R6 denotes H, A, OA, NH_2, -NH-COA, -CO-NHA, Hal, NAA, -NH-CO-Alk-NYY, -NH-Alk-Het^3, -NH-CO-NH_2, -NH-CO-Het^3, -CO-NH-Het^3, -NH-CO-Alk-OH or -NH-CO-Alk-NH-COOA;

R2 denotes phenyl, pyridyl, pyrazolyl or pyrazinyl, each of which can be mono-, di- or trisubstituted by at least one substituent selected from the group of F, Cl, Br, CH_3, CF_3, CN, OCH_3, OCF_3;

Y denotes H or A;

A denotes unbranched or branched alkyl having 1-4 C atoms, in which 1-5 H atoms can be replaced by F and/or Cl;

Alk denotes alkylene having 1-3 C atoms;


Het^3 denotes piperazine, piperidine, morpholine, pyrrolidine, piperidone, morpholinone or pyrrolidone, which can be monosubstituted by A, Hal, COOY or NYY;


and


Hal denotes F, Cl or Br;


and/or physiologically acceptable salts thereof.


7. Compounds according to any of claims 1 to 6, which are selected from the group of:


1 


2 


3 


5 


6 


9 


65 

67 


70 


71 


72 


73 


10 


11 


12 


13 


14 


15 


77 


78 


80 


81 


82 


85 


16 


17 


18 


20 


21 


22 


86 


87 


88 


89 


90 


91 


23 


25 


26 


28 


29 


30 


92 


94 


95 


98 


99 


100 


32 


33 


34 


37 


38 


40 


104 


105 


106 


107 


109 


110 


41 


42 


43 


44 


47 


48 


111 


112 


113 


114 


115 


117 


49 


50 


51 


52 


53 


54 


121 


125 


129 


130 


131 


133 


55 


57 


58 


60 


62 


63 

135 

139 

141 


143 

144 

and/or physiologically acceptable salts thereof.

8. Process for manufacturing a compound of formula (I) comprising the steps of:


(a) reacting a compound of formula (IV)



(IV)

wherein R7 denotes Hal, OY or NYY; and
R2, R3, R4, Hal and Y have the meaning according to claim 1,


with a compound of formula (V)



(V)

wherein X, R1, W1, W2, W3, W5 and W6 have the meaning according to claim 1 under the proviso that R1, R5 together are excluded,

to yield a compound of formula (I)



(I)

wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim 1 under the proviso that R1, R5 together are excluded,

and optionally

(b) converting a base or an acid of the compound of formula (I) into a salt thereof.

9. Use of compounds according to any of claims 1 to 7 and/or physiologically acceptable salts thereof for inhibiting ATP consuming proteins in-vitro, preferably TGF-beta receptor kinase, wherein an IC50 of the compounds amounts to less than 1 µM, preferably less than 0.1 µM.

10. Medicament comprising at least one compound according to any of claims 1 to 7 and/or physiologically acceptable salts.

11. Pharmaceutical composition comprising as active ingredient an effective amount of at least one compound according to any of claims 1 to 7 and/or physiologically acceptable salts thereof together with pharmaceutically tolerable adjuvants, optionally in combination with at least another active ingredient selected from the group of (1) estrogen receptor modulators, (2) androgen receptor modulators, (3) retinoid receptor modulators, (4) cytotoxic agents, (5) antiproliferative agents, (6) prenyl-protein transferase inhibitors, (7) HMG-CoA reductase inhibitors, (8) HIV protease inhibitors, (9) reverse transcriptase inhibitors and (10) further angiogenesis inhibitors.

12. Compounds according to any of claims 1 to 7 and/or physiologically acceptable salts thereof for use in the prophylactic or therapeutic treatment and/or monitoring of diseases selected from the group of cancer, tumor growth, metastatic growth, fibrosis, restenosis, HIV infection, neurodegenerative disorders, atherosclerosis, inflammation and disorders of wound healing, angiogenesis, cardiovascular system, bone, CNS and/or PNS.